




The relative strengths and weaknesses of Bioxytran INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bioxytran INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 3.1% points. The greatest weakness of Bioxytran INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 129% points.

The company's Economic Capital Ratio, given in the ranking table, is 40%, being 190% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	513
Cost of Goods Sold	0
Intangible Assets	145
Liabilities, Current	3,250
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	740
Other Liabilities	0
Other Net Income	-281
Other Revenues	0
Property and Equipment	0
Research and Development	454
Selling, General and Administrative Expense	648

Output Variable	Value in 1000 USD
Assets	659
Liabilities	3,250
Expenses	1,843
Revenues	0
Stockholders Equity	-2,591
Net Income	-2,123
Comprehensive Net Income	-2,123
BaseVar	3,016
ECR before LimitedLiability	-398%
Economic Capital Ratio	40%